AEON | tickerfilter.com

Fundamental analysis

45%

Profitability 53%

Dept financing 43%

Liquidity 34%

Performance 40%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-3.67%

1 Month

-9.48%

3 Months

-12.50%

6 Months

15.38%

1 Year

150.00%

2 Year

-73.68%

Key data

Stock price

$1.05

P/E Ratio

N/A

DAY RANGE

$0.98 - $1.07

EPS

$5.58

52 WEEK RANGE

$0.39 - $1.45

52 WEEK CHANGE

$150.00

MARKET CAP

0.000

YIELD

N/A

SHARES OUTSTANDING

11.838 M

DIVIDEND

$0.00

EX-DIVIDEND DATE

02-26-2025

NEXT EARNINGS DATE

05-13-2025

BETA

0.40

PUBLIC FLOAT

AVERAGE 10 VOLUME

$108,431

AVERAGE 30 VOLUME

$143,170

Company detail

CEO: Marc Forth
Region: US
Website: aeonbiopharma.com
Employees: 0
IPO year: 2021

Issue type: Common Stock
Market: NYSE American
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed a Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine. AEON Biopharma, Inc. is based in Irvine, California.

AEON - AEON Biopharma, Inc.